Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention
NCT ID: NCT00404781
Last Updated: 2009-10-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
305 participants
INTERVENTIONAL
2006-06-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Atorvastatin Versus Pravastatin on Platelet Inhibition by Clopidogrel
NCT00405717
Anticoagulation in Stent Intervention
NCT01141153
Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients
NCT01779401
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
NCT02554721
Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation
NCT01094457
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
optimal antiplatelet
cilostazol in addition to aspirin and clopdidogrel for pts with clopidogrel resistance
cilostazol in addition to aspirin and clopidogrel
standard antiplatelet
aspirin and clopidogrel for all patients
cilostazol in addition to aspirin and clopidogrel
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cilostazol in addition to aspirin and clopidogrel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients undergoing selective or emergent PCI
Exclusion Criteria
* ST-segment elevated myocardial infarction
* contraindications of antiplatelet therapy
* history of intracranial bleeding
* known bleeding disorders
* severe liver or kidney disease
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shenyang Northern Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shenyang Northern Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Yaling Han, M.D.
Role: PRINCIPAL_INVESTIGATOR
Shenyang Northern Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Northern Hospital
Shenyang, Liaoning, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NH-2006-C001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.